Thyrocare Technologies Ltd (THYROCARE) AI Stock Analysis

• Market Cap: ₹59.37B
• Dividend Yield: 0.68%
• Average Volume (3M): 56.30K
• Price to Earnings (P/E): 61.2
• Beta (1Y): 0.50
• Revenue Growth: 22.36%
• EPS Growth: 52.00%
• Country: IN
• Employees: 1,693
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 4.30
• Shares Outstanding: 159,165,310
• 10 Day Avg. Volume: 44,587
• 30 Day Avg. Volume: 56,302
• PEG Ratio: 0.49
• Price to Book (P/B): 2.35
• Price to Sales (P/S): 1.87
• P/FCF Ratio: 8.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 10.1
• Revenue Forecast (FY): ₹8.17B

• Rating: 69 Neutral
• Price Target: ₹408.00 ▼(-11.13% Downside)
• Action: Downgraded Date: 12/03/25
• Date: Action: Downgraded 12/03/25

Thyrocare Technologies Ltd shows strong financial performance with robust revenue growth and efficient cash flow management, which are the primary drivers of the stock score. Technical analysis indicates a positive trend, though valuation metrics suggest the stock is priced at a premium. The absence of earnings call data and notable corporate events limits additional insights.

Positive Factors

Consistent revenue and EPS growth

Sustained top-line growth (~21% YoY) alongside strong EPS expansion (≈57%) signals durable demand for diagnostic services and improving operating leverage. Over 2–6 months this underpins cash generation, reinvestment capacity, and supports scale-driven margin resilience versus peers.

Centralized automated lab network and broad test menu

A centralized, automated lab model plus a broad test menu creates structural cost advantages and throughput scale. This supports consistently lower per-test costs, easier new-test rollouts, and competitive distribution economics that remain relevant beyond short-term cycles.

Strong cash flow generation and healthy balance sheet

Rising operating cash flow, positive free cash flow growth, and an improving equity ratio provide durable financial flexibility for capex, network expansion or M&A. Low leverage reduces refinancing risk and supports sustained investment in capacity and technology.

Negative Factors

Rising capital expenditure burden

Material ongoing capex, while supporting capacity, can strain free cash flow if revenue growth slows. Over several months higher capex increases funding needs, reduces optionality for dividends or buybacks, and can elevate liquidity risk if not matched by steady volume growth.

Slight net margin compression

A decline in net margin points to rising operating or financing costs that could erode the benefits of scale. If persistent, margin pressure would reduce cash conversion and limit resources for strategic initiatives, requiring sustained cost-control to preserve profitability.

Reliance on test volumes and channel partners

Business performance depends on sustaining high test volumes and partner throughput. Volume sensitivity and partner economics expose the company to utilization swings, competitive pricing and partner concentration, which could meaningfully impact revenue and margins over months.

Thyrocare Technologies Ltd Business Overview & Revenue Model

Company Description

Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.

How the Company Makes Money

Thyrocare makes money by providing diagnostic testing services and collecting fees for processing patient samples in its laboratories. Its core revenue stream comes from pathology lab test volumes (including individual tests and bundled wellness/preventive health check-up packages), where samples are collected via a network of collection points/channel partners and then processed at centralized labs to achieve scale and cost efficiency. Revenue is generated per test/package sold to end customers (direct-to-consumer) and via business-to-business arrangements where hospitals, clinics, and independent collection centers route patient samples to Thyrocare for testing and share economics through agreed pricing/discount structures. Additional earnings can come from expanding test menus, increasing throughput from existing lab infrastructure, and leveraging distribution/collection partnerships that drive higher sample inflows; specific partnership terms or revenue breakdowns are null if not publicly specified in the provided context.

Thyrocare Technologies Ltd Financial Statement Overview

Summary

Thyrocare Technologies Ltd exhibits strong financial health with consistent revenue growth, solid profitability margins, and a stable balance sheet. The company effectively manages its cash flows, ensuring operational efficiency and strategic investments. While there are areas for improvement, such as optimizing operational costs and managing capital expenditures, the overall financial outlook is positive, supporting future growth and stability.

Income Statement

Thyrocare Technologies Ltd has demonstrated strong revenue growth with a significant increase from 2024 to 2025, indicating robust market positioning. The gross profit margin has improved, reflecting efficient cost management. However, the net profit margin has seen a slight decrease, suggesting increased operational costs or financial expenses. Overall, the income statement shows a healthy trajectory with some areas for cost optimization.

Balance Sheet

The company maintains a solid equity base with an improving equity ratio, indicating financial stability. The debt-to-equity ratio is low, which minimizes financial risk, although there is a small increase in total debt. Return on equity remains strong, highlighting effective use of shareholder funds. The balance sheet reflects a stable financial structure with room for leveraging growth opportunities.

Cash Flow

Operating cash flow has increased, supporting operational sustainability. The free cash flow growth rate is positive, indicating effective capital management. The operating cash flow to net income ratio suggests high-quality earnings. However, capital expenditure remains significant, which may impact future liquidity if not managed carefully. Overall, cash flow statements show a healthy cash position with strategic investments.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	7.63B	6.87B	5.72B	5.27B	5.89B	4.95B
Gross Profit	5.90B	4.96B	1.81B	3.63B	4.19B	3.31B
EBITDA	2.45B	2.04B	1.48B	1.31B	2.64B	1.84B
Net Income	1.28B	915.10M	707.60M	644.90M	1.76B	1.13B
Balance Sheet
Total Assets	6.80B	6.93B	6.44B	6.33B	6.08B	5.46B
Cash, Cash Equivalents and Short-Term Investments	1.92B	1.92B	1.77B	1.51B	1.39B	1.18B
Total Debt	246.80M	246.80M	423.40M	233.10M	207.00M	84.90M
Total Liabilities	1.46B	1.46B	1.16B	975.00M	810.90M	1.19B
Stockholders Equity	5.34B	5.47B	5.27B	5.34B	5.27B	4.27B
Cash Flow
Free Cash Flow	1.11B	1.46B	1.06B	856.60M	755.80M	877.70M
Operating Cash Flow	1.27B	1.91B	1.68B	1.29B	1.13B	1.16B
Investing Cash Flow	47.10M	-525.20M	-912.80M	-389.90M	-235.70M	-502.30M
Financing Cash Flow	-1.18B	-1.30B	-848.00M	-861.80M	-894.10M	-615.70M

Thyrocare Technologies Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 459.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:THYROCARE, the sentiment is Negative. The current price of 459.1 is above the 20-day moving average (MA) of 376.71, above the 50-day MA of 408.39, and above the 200-day MA of 414.09, indicating a bearish trend. The MACD of -13.14 indicates Negative momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 41.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:THYROCARE.

Thyrocare Technologies Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIJAYA	75 Outperform	₹90.63B	63.11	―	0.20%	16.71%	13.92%
THYROCARE	69 Neutral	₹59.37B	61.22	―	0.68%	22.36%	52.00%
METROPOLIS	61 Neutral	₹92.78B	60.35	―	0.21%	15.41%	5.93%
KRSNAA	58 Neutral	₹18.61B	38.37	―	0.38%	11.51%	21.56%
MOREPENLAB	57 Neutral	₹19.33B	20.54	―	0.49%	-0.29%	-29.04%
MEDIASSIST	54 Neutral	₹22.71B	205.09	―	0.92%	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Thyrocare Technologies Ltd Corporate Events

Thyrocare boosts Tanzania subsidiary with fresh capital infusion

Thyrocare Technologies Ltd has infused an additional USD 475,000, equivalent to about INR 4.33 crore, into its Tanzanian subsidiary, Thyrocare Laboratories (Tanzania) Ltd, by subscribing to compulsorily convertible irredeemable preference shares. The related-party transaction, executed on an arm’s-length basis, is aimed at strengthening the subsidiary’s working capital and operational capabilities in the healthcare services sector, supporting its turnaround given a modest turnover of INR 1.84 crore and negative net worth as of December 31, 2025.

The capital infusion underscores Thyrocare’s commitment to consolidating and scaling its international diagnostics footprint, particularly in Tanzania where the unit mirrors the parent’s core line of diagnostic and healthcare services. By bolstering the financial position of Thyrocare Tanzania, the company is seeking to enhance service delivery, stabilize the subsidiary’s balance sheet, and improve its long-term strategic positioning in an emerging healthcare market.

Thyrocare Wins Dual Honours at National Diagnostics Forum 2026

Thyrocare Technologies Limited announced that it has received two major recognitions at the 4th Edition of the National Diagnostics Forum & Awards 2026, organized by Voice of Healthcare in Mumbai. The company was named “Best Diagnostic Lab Chain of the Year” and “Patient-Centric Diagnostic Company of the Year,” underscoring its strategic positioning as a leading, customer-focused diagnostics provider and reinforcing its reputation for quality, affordability, and operational excellence in India’s competitive diagnostics market.

Thyrocare Schedules January 28 Earnings Call to Discuss Q3 FY26 Results

Thyrocare Technologies Limited has scheduled an earnings conference call with analysts and investors on January 28, 2026, to discuss its unaudited financial results for the quarter and nine months ended December 31, 2025. The call, which will feature senior management including the managing director and CEO, CFO, and strategy and investor relations lead, underscores the company’s ongoing engagement with the capital markets and provides stakeholders with an opportunity to gain deeper insight into recent financial performance and operational trends.

Thyrocare Auditor Converts to LLP Without Change in Audit Mandate

Thyrocare Technologies has announced that its statutory auditor, M/s. M S K A & Associates, Chartered Accountants, has converted from a partnership firm into a Limited Liability Partnership and will now operate as M S K A & Associates LLP, with updated registration details under the LLP and ICAI frameworks. The company emphasized that this structural change in the audit firm does not affect the scope or continuity of the audit engagement, does not amount to a resignation or fresh appointment, and therefore is not expected to disrupt the company’s audit process or governance arrangements, offering continuity and stability for stakeholders relying on its financial reporting.

Thyrocare Appoints Industry Veteran Rajdeep Panwar as Chief Commercial Officer

Thyrocare Technologies Limited has appointed senior healthcare and diagnostics professional Mr. Rajdeep Panwar as Chief Commercial Officer, categorised as Senior Management Personnel, with effect from 5 January 2026, following approval by the Board of Directors based on the Nomination and Remuneration Committee’s recommendation. With over 21 years of experience leading large diagnostic networks and commercial functions at organisations including Medanta Labs, Apollo Diagnostics and Dr. Lal PathLabs, Panwar’s mandate is expected to strengthen Thyrocare’s commercial strategy, network expansion and operational scaling across diverse markets, reinforcing its competitive position in India’s diagnostics sector.

Thyrocare Names Industry Veteran Rajdeep Panwar as Chief Commercial Officer

Thyrocare Technologies Limited has appointed senior diagnostics professional Rajdeep Panwar as its Chief Commercial Officer, effective January 5, 2026, following approval by the company’s Board of Directors based on the Nomination and Remuneration Committee’s recommendation. Panwar brings over 21 years of experience in leading diagnostic networks, laboratory operations and commercial functions at major healthcare organisations including Medanta Labs, Apollo Diagnostics and Dr. Lal PathLabs, and his expertise in P&L management, network expansion, digital diagnostics and accreditation is expected to strengthen Thyrocare’s senior management bench and support the expansion and scaling of its diagnostic operations across diverse markets.